title: Effect of hormone replacement therapy on spinal bone mineral density and T lymphocyte subsets in premature ovarian failure and Turner's syndrome.
abstract: OBJECTIVE
  Our purpose was to evaluate the effect of hormone replacement therapy (HRT) on bone metabolism and the immunological change in premature ovarian failure (POF) and Turner's syndrome.
  
  
  METHODS
  The study was conducted on 17 POF patients, 10 Turner's syndrome patients and 35 control subjects aged 20-40 years. Bone mineral density (BMD) of lumbar vertebra by dual energy X-ray absorptiometry, serum bone metabolic parameters and T lymphocyte subsets in the peripheral blood were investigated.
  
  
  RESULTS
  The untreated and treated patients of POF (0.829 +/- 0.077, 0.918 +/- 0.094 g/cm2) and the untreated and treated patients of Turner's syndrome (0.647 +/- 0.037, 0.885 +/- 0.148 g/cm2) showed spinal osteopenia compared with the control group (1.039 +/- 0.107 g/cm2). They showed a significantly lower percentage of CD4 and a ratio of CD4/CD8 in T lymphocytes as compared with the control group before HRT.
  
  
  CONCLUSIONS
  POF and Turner's syndrome patients showed marked spinal osteopenia and abnormal T lymphocytes subsets. HRT slightly improved their BMD and immunological status.
authors.affiliation: Department of Obstetrics and Gynecology, Niigata University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kurabayashi
authors.forename: M
authors.initials: M
authors.lastname: Yasuda
authors.forename: T
authors.initials: T
authors.lastname: Fujimaki
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Oda
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D008656:Mestranol / Q000627:therapeutic use; D016649:Primary Ovarian Insufficiency / Q000188:drug therapy* / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000187:drug effects*; D014424:Turner Syndrome / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D008656:Mestranol; D017258:Medroxyprogesterone Acetate